Associated Genetic Biomarkers
NCI Definition: An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors. 
Neurofibromas most frequently harbor alterations in NF1 .
NF1 Mutation and NF1 Nonsense are the most common alterations in neurofibroma .
There are 8 clinical trials for neurofibroma, of which 5 are open and 3 are completed or closed. Of the trials that contain neurofibroma as an inclusion criterion, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open).
NF1 is the most frequent gene inclusion criterion for neurofibroma clinical trials .
Aminolevulinic acid, cabozantinib, and photodynamic therapy are the most common interventions in neurofibroma clinical trials.
Significant Genes in Neurofibroma
BRAF is an inclusion eligibility criterion in 1 clinical trial for neurofibroma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neurofibroma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
NF1 is altered in 43.48% of neurofibroma patients .
NF1 is an inclusion eligibility criterion in 7 clinical trials for neurofibroma, of which 4 are open and 3 are closed. Of the trials that contain NF1 status and neurofibroma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.